TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06046417
Drug: Pramlintide
Normalized name: Pramlintide
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pramlintide delivered in a basal-bolus manner.
Study: NCT06046417
Drug: Lyumjev
Normalized name: Lyumjev
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lyumjev delivered in a basal-bolus manner.
Study: NCT06367387
Drug: Patient-Oriented Dosing (POD)
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-oriented dosing (POD) is a promising approach to using buprenorphine or buprenorphine/naloxone to treat individuals with both OUD and chronic pain. It is based on existing evidence related to buprenorphine for the treatment of pain. POD allows participants to receive a daily dosage of bup up to 32mg/day, split up to 4 times per day.~A response-guided dosing strategy, in which buprenorphine or buprenorphine/naloxone doses will be titrated based on a participant response, will be used to identify a dose regimen that is safe and effective. Due to inter-individual pharmacokinetic/pharmacodynamic variability, POD dosing will be individualized based on a participant's pain intensity and interference.
Study: NCT06367387
Drug: Standard Buprenorphine Dosing Condition
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will continue standard buprenorphine or buprenorphine/naloxone dosing as part of normal clinical care.
Study: NCT05780034
Drug: AC676
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: AC676 will be given orally (PO) on a 28-day cycle.
Study: NCT05116826
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg Twice Daily for 7 days
Study: NCT05029453
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In experimental group, the drug used with apatinib and chemotherapy.
Study: NCT05761470
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle.~Fluzoparibat at a fixed dose of 100mg BID, each 21-day cycle. Nab-paclitaxel at a fixed dose of 260 milligrams via intravenous (IV) infusion on Days 1 each 21-day cycle.
Study: NCT05761470
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzoparib
Study: NCT05761470
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel
Study: NCT00002257
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05426018
Drug: SY-009 capsules
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 capsules each time (3 test drugs), 3 times a day (oral administration before breakfast, lunch, dinner or with meals)
Study: NCT06220552
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200mg D1, Q3W
Study: NCT05755659
Drug: Fosaprepitant Dimeglumine for Injection
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The specification of Fosaprepitant Dimeglumine for injection is 150 mg, and the usage and dosage is: when preventing nausea and vomiting caused by HEC, this product is used in combination with dexamethasone and 5-HT3 antagonist. The dosage of Fosaprepitant Dimeglumine for injection is 150 mg, and the infusion time is 20-30 minutes. The intravenous infusion is completed 30 minutes before the beginning of chemotherapy on the first day.
Study: NCT06437951
Drug: Fexuprazan Injection_part 2
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg
Study: NCT06437951
Drug: Fexuprazan Injection_part 3
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg
Study: NCT05613777
Drug: BI 425809
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 425809
Study: NCT04693039
Drug: Phenlarmide
Normalized name: Octanedioic acid hydroxyamide phenylamide
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.
Study: NCT05395195
Drug: Erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin injections (500u/kg) x 9 doses
Study: NCT05367700
Drug: HS-10382(Part 1: Dose escalation)
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple dose(s) of HS-10382 once daily.
Study: NCT05367700
Drug: HS-10382(Part 2: Dose expansion)
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10382 is administered orally once daily.
Study: NCT06112353
Drug: Neostigmine Injectable Solution
Normalized name: neostigmine Injectable Solution
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Examine GI-2 recovery
Study: NCT06112353
Drug: Sugammadex injection
Normalized name: sugammadex Injection
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Examine GI-2 recovery
Study: NCT06463782
Drug: 68Ga-LNC1007 Injection
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant will receive a single intravenous injection with 0.05 mCi/kg (according to the participants' body weight) 68Ga-LNC1007 Injection on the scan bed. The final dose of the drug is allowed to fluctuate within the 20% range, but not below 3 mCi. A 10 mL normal saline flush will be given after the completion of the injection to ensure the residue is injected.
Study: NCT05337553
Drug: taldefgrobep alfa
Normalized name: Taldefgrobep alfa
DrugBank: Talditercept alfa (DB16337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DB Phase: 35 mg/50 mg weekly subcutaneous injection
Study: NCT05337553
Drug: taldefgrobep alfa
Normalized name: Taldefgrobep alfa
DrugBank: Talditercept alfa (DB16337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extension Phase: 35 mg/50 mg weekly subcutaneous injection
Study: NCT06044506
Drug: Autologous Natural Killer Cell Therapy
Normalized name: Hongo Killer
DrugBank: Natural Killer Cell (DB15721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The therapy will be administered intravenously
Study: NCT04853446
Drug: Dexamethasone 12 mg
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two identically appearing, opaque capsules will be administered: one capsule containing 12 mg of dexamethasone and one capsule containing placebo.
Study: NCT04853446
Drug: Dexamethasone 24 mg
Normalized name: dexAMETHasone 24 mg/mL intravenous solution
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two identically appearing, opaque capsules will be administered: two capsules each containing 12mg dexamethasone.
Study: NCT05970705
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: this anti-angiogenesis targeting drug is one of the standard third-line treatment options for patients with metastatic colorectal cancer
Study: NCT04341155
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in experimental arms will receive i.v. dexamethasone 20 mg (4 ampules = 20mL) for 7 days
Study: NCT06329258
Drug: Enstilar
Normalized name: Enstilar
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Add on Enstilar
Study: NCT06329258
Drug: Deucravacitinib
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg QD
Study: NCT05162274
Drug: Lazertinib(G001)
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current formulation
Study: NCT05162274
Drug: Lazertinib(G002)
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation
Study: NCT06375486
Drug: Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
DrugBank: Ivonescimab (DB18931)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All enrolled subjects will receive Ivonescimab（AK112，a PD-1/VEGF bispecific antibody，20mg/kg Q3W) in combination with HAIC (utilizing the FOLFOX chemotherapy regimen)
Study: NCT05422183
Drug: Envafolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg，sc，d1，Q3W
Study: NCT05422183
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg(BW\<60 kg) OR 12 mg(BW≥60 kg)，po，qd，d1-21，Q3W
Study: NCT05422183
Drug: VP-16
Normalized name: Provp-16i
DrugBank: Etoposide toniribate (DB17255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/d, po,d1-14，Q3W
Study: NCT06238635
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Humanized monoclonal antibody, 50mg/mL type 1 borosilicate clear glass vial, via intravenous infusion per protocol.
Study: NCT06238635
Drug: Cobolimab
Normalized name: Cobolimab
DrugBank: Cobolimab (DB16372)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humanized anti-TIM-3 monoclonal antibody, 20mg/mL single-use vial, via intravenous infusion per protocol.
Study: NCT01433393
Drug: TAK-875
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05559437
Drug: Levo-bupivacaine 0.25
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The blockade of ilioinguinal/iliohypogastric nerves in the anterior abdominal wall has improved postoperative analgesia after open inguinal hernia repair. Other new blocks needs to be investigated
Study: NCT00417014
Drug: chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00417014
Drug: procarbazine hydrochloride
Normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00417014
Drug: vinblastine sulfate
Normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05774028
Drug: Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P-GEMD regimen (Every 3 weeks as a cycle, a total of 6 cycles) : Pegaspargase 3750 IU, d2; Gemcitabine 1000mg/m2, d1; Etoposide 65mg/m2, d2-d4; Mitoxantrone hydrochloride liposome 12mg/m2, d1; Dexamethasone 40mg/d, d1- d4.
Study: NCT04983979
Drug: Sodium Zirconium Cyclosilicate
Normalized name: sodium zirconium cyclosilicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sachets of 5g or 10g given OD titrated to serum potassium
Study: NCT05843292
Drug: Taxane and Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nab-paclitaxel 100mg/m2+ Carboplatin AUC2 by intravenous (IV) infusion on day1, day8 and day15, every 4 weeks, for 4 cycles.~or Docetaxel 75mg/m2+ Carboplatin AUC5 by intravenous (IV) infusion on day1, every 3 weeks, for 4 cycles.~or Paclitaxel 80mg/m2+ Carboplatin AUC2 by intravenous (IV) infusion on day1, day8 and day15, every 4 weeks, for 4 cycles.
Study: NCT05843292
Drug: Short-term Sintilimab
Normalized name: hydrogen peroxide
DrugBank: Sintilimab (DB15765)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sintilimab 200mg by intravenous (IV) infusion on day1, every 3 weeks, for 2 cycles.
Study: NCT04588129
Drug: LB-102
Normalized name: LB-102
DrugBank: LB-102 (DB19214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (N-Methyl amisulpride)
Study: NCT00000611
Drug: hormone replacement therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000611
Drug: estrogens
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000611
Drug: estrogen replacement therapy
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000611
Drug: vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05028114
Drug: AC-OLE-01
Normalized name: G-ol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tricaprilin Formulation
Study: NCT05028114
Drug: AC-OLE-02
Normalized name: G-ol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tricaprilin Formulation
Study: NCT05028114
Drug: AC-OLE-03
Normalized name: G-ol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tricaprilin Formulation
Study: NCT05028114
Drug: AC-OLE-04
Normalized name: G-ol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tricaprilin Formulation
Study: NCT05028114
Drug: AC-OLE-05
Normalized name: G-ol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tricaprilin Formulation
Study: NCT05028114
Drug: AC-OLE-06
Normalized name: G-ol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tricaprilin Formulation
Study: NCT05028114
Drug: AC-OLE-07
Normalized name: G-ol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tricaprilin Formulation
Study: NCT05028114
Drug: AC-OLE-08
Normalized name: G-ol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tricaprilin Formulation
Study: NCT05028114
Drug: AC-OLE-09
Normalized name: G-ol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tricaprilin Formulation
Study: NCT05028114
Drug: AC-OLE-010
Normalized name: G-ol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tricaprilin Formulation
Study: NCT05028114
Drug: AC-OLE-P
Normalized name: p-Menthan-3-ol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to tricaprilin formulation
Study: NCT04148781
Drug: Fampridine SR
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fampridine-SR 10 mg twice daily for 8 weeks
Study: NCT05141552
Drug: Dapagliflozin 10Mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In both group, subjects keep blood purification and anti heart failure treatment, including ARNI, RASi, Aldosterone inhibitors and beta receptor blocker.
Study: NCT06246695
Drug: Jaktinib Hydrochloride Tablets
Normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Jaktinib 100 mg for 1 day
Study: NCT06246695
Drug: Itraconazole capsule
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Itraconazole 200 mg for 9 day
Study: NCT06246695
Drug: Rifampicin Capsules
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Rifampicin 600 mg for 11 day
Study: NCT06071520
Drug: Fostamatinib
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patient treated with fostamatinib in the period described
Study: NCT05794477
Drug: Carboplatin/Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
Study: NCT05794477
Drug: Paclitaxel/Nab-Paclitaxel/Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.
Study: NCT05386186
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initiate glimepiride 1-4mg once daily as an add-on therapy to metformin and adjust the glimepiride dosage to 1-6 mg once daily in the first 12 weeks according to the diabetes management guideline recommended by the Chinese Diabetes Society.
Study: NCT05386186
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Add sitagliptin 100mg once daily in all patients randomized to this arm.
Study: NCT06247670
Drug: CMP-CPS-001
Normalized name: CP
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CMP-CPS-001 consists of an antisense oligonucleotide solution that will be administered subcutaneously.
Study: NCT04811014
Drug: Buprenorphine, Naloxone Drug Combination
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 8mg of buprenorphine/2mg of naloxone to initiate MOUD treatment and bridge, if necessary, until referral to MOUD clinic can be made for ongoing treatment
Study: NCT00297921
Drug: tandutinib
Normalized name: Tandutinib
DrugBank: Tandutinib (DB05465)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03684564
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tablet 15 mg twice daily for 24 months
Study: NCT03684564
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral anticoagulant given as standard of care in the RISAPS trial to maintain a target INR of 3.5 (range 3.0-4.0) for 24 months
Study: NCT05549492
Drug: Ropivacaine 0.25%-NaCl 0.9% Injectable Solution
Normalized name: ROPivacaine 0.25%-NaCl 0.9% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The pain level of the cases is evaluated by means of the digital pain (numeric rating) scale from 0 to 10 in which 0 means no pain and 10 means the worst pain as well as the duration of pain relief and the need for another dose of the same analgesic or other. The pain level is evaluated again if it is present.
Study: NCT04905953
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal injection of two doses of neostigmine (10 \& 20 mic) during spinal anesthesia for cesarean section.
Study: NCT00000877
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000877
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05208047
Drug: CGT9486 plus sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive both CGT9486 and sunitinib orally until study stopping rules are met.
Study: NCT05208047
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive sunitinib until steady state then both sunitinib and CGT9486 orally until study stopping rules are met.
Study: NCT05208047
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive sunitinib orally until study stopping rules are met.
Study: NCT05208047
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive a single-dose of midazolam on Day 1 and Day 16
Study: NCT05208047
Drug: CGT9486 plus sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive CGT9486 orally starting on Day 2 and sunitinib starting on Day 16 until study stopping rules are met.
Study: NCT04530383
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500-1000 mg twice daily
Study: NCT06175377
Drug: Short dual Aspirin/Clopidogrel therapy
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aspirin will be prescribed as part of the patient's normal course of care, according to current recommendations. The second antiplatelet agent will be clopidogrel, the duration of which will vary according to the randomization group of each patient included. Patients will be treated for 1 month.
Study: NCT05495321
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once every other day, for 6 months.
Study: NCT01632826
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg daily for 21 days in a 28 day cycle until disease progression or other reasons for treatment discontinuation
Study: NCT06563999
Drug: Sunvozertinib
Normalized name: Sunvozertinib
DrugBank: Sunvozertinib (DB18925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg orally once a day, 28 days as one cycle.
Study: NCT06563999
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg orally once a day, 28 days as one cycle.
Study: NCT06563999
Drug: Pralsetinib
Normalized name: pralsetinib
DrugBank: Pralsetinib (DB15822)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 400 mg orally once a day, 28 days as one cycle.
Study: NCT06563999
Drug: Larotrectinib
Normalized name: Larotrectinib
DrugBank: Larotrectinib (DB14723)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg orally twice daily, 28 days as one cycle.
Study: NCT06563999
Drug: Savolitinib
Normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg or 400 mg (weight \<50 kg) orally once a day, 28 days as one cycle.
Study: NCT06563999
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg orally once a day, 28 days as one cycle.
Study: NCT06563999
Drug: Dabrafenib+Trametinib
Normalized name: Dabrafenib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg orally twice daily, 28 days as one cycle. Trametinib 150 mg orally twice daily, 28 days as one cycle.
Study: NCT06563999
Drug: Glecirasib
Normalized name: Glecirasib
DrugBank: Glecirasib (DB18744)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg daily orally, 28 days as one cycle.